Diversity of Humira biosimilar launches reveals the difficulty of dethroning AbbVie’s megablockbuster

Sandoz, Boehringer Ingelheim, Samsung and others are now taking their shot at AbbVie’s megablockbuster Humira, with launches of their biosimilars on Saturday, and myriad approaches to take market share that AbbVie has so far defended well against.

Boehringer, which is the only company with an interchangeable biosimilar on the market so far, confirmed that the lowest-cost version of its interchangeable won’t launch until next year, and the version that launched on July 1 is priced with only a slight discount to Humira.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Cardiologist’s Date Rape Verdict; Feds Come Down on DOAC Price; POC Test for HF?

In a highly publicized case, a former Denver cardiologist was found guilty of 35 out of 38 counts of sexual assault related to women he

August 21, 2024

Light activity holds promise for combating childhood obesity

Increased sedentary time from childhood through young adulthood caused increased body fat and abdominal fat in a new follow-up study.

December 13, 2023

Influence of healthy lifestyle habits on chronic disorders

The health benefits of regular exercise, a healthy diet, and adequate sleep.

November 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.